keyword
MENU ▼
Read by QxMD icon Read
search

Commentary

keyword
https://www.readbyqxmd.com/read/28449071/letter-commentary-deep-brain-stimulation-as-clinical-innovation-an-ethical-and-organizational-framework-to-sustain-deliberations-about-psychiatric-deep-brain-stimulation
#1
Eric Racine, Tejas Sankar, Philip Leger, Emily Bell
No abstract text is available yet for this article.
April 25, 2017: Neurosurgery
https://www.readbyqxmd.com/read/28449037/commentary-on-cosmetic-liposuction-preoperative-risk-factors-major-complication-rates-and-safety-of-combined-procedures
#2
Nathaniel L Villanueva, Jeffrey M Kenkel
No abstract text is available yet for this article.
April 26, 2017: Aesthetic Surgery Journal
https://www.readbyqxmd.com/read/28448313/commentary-on-a-30-minute-monthly-live-webinar-based-journal-club-activity-alters-the-self-reported-behaviors-of-dermatologic-surgeons
#3
M Laurin Council
No abstract text is available yet for this article.
April 12, 2017: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
https://www.readbyqxmd.com/read/28448199/deferiprone-for-the-treatment-of-transfusional-iron-overload-in-thalassemia
#4
Janet L Kwiatkowski, Ami Belmont
Transfusional iron overload can lead to hepatic fibrosis, arrhythmias and congestive heart failure and a number of endocrinopathies. Deferiprone is an oral iron chelator recently approved for use in the United States as a second line agent for the treatment of transfusional iron overload in patients with thalassemia. Areas covered: This article will review the data regarding the efficacy of deferiprone for iron chelation and prevention and reversal of iron related complications, the drug's adverse effect profile, and the use of this drug in combination regimens...
April 27, 2017: Expert Review of Hematology
https://www.readbyqxmd.com/read/28448170/mechanical-circulatory-support-devices-methods-to-optimize-hemodynamics-during-use
#5
Ben Bow Chung, Gabriel Sayer, Nir Uriel
Introduction Mechanical circulatory support (MCS) is an increasingly utilized mode of therapy in the management of advanced heart failure, both as bridge to heart transplantation and destination therapy. As MCS becomes more prevalent, it is ever more important to understand the complex hemodynamics of these devices, as well as the strategies for hemodynamic optimization. Areas Covered This review provides an overview of hemodynamics in the normal human heart and the failing heart. We discuss the various short-term mechanical circulatory support devices and their hemodynamic consequences...
April 27, 2017: Expert Review of Medical Devices
https://www.readbyqxmd.com/read/28447884/do-micrornas-play-a-role-in-the-activity-of-plant-based-vaccines
#6
Sergio Rosales-Mendoza, Jorge A Salazar-González
An important trend in vaccinology is the development of oral vaccines based on genetically modified plants. Areas covered: Several studies have suggested that dietary microRNAs from plants and other organisms are bioavailable upon oral ingestion exerting biological events in the host such as the modulation of gene expression in several cell types. Since oral plant-based vaccines rely on whole cells as vaccine delivery vehicles, miRNAs could play a role in the immunogenic activity of this type of vaccine. In the present report, this hypothesis is discussed under the light of recent evidence on the immunomodulatory activity exerted by miRNAs using in vitro and in vivo evaluations...
April 27, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28447487/tissue-engineered-vascular-grafts-current-state-of-the-field
#7
Chin Siang Ong, Xun Zhou, Chen Yu Huang, Takuma Fukunishi, Huaitao Zhang, Narutoshi Hibino
Conventional synthetic vascular grafts are limited by the inability to remodel, as well as issues of patency at smaller diameters. Tissue-engineered vascular grafts (TEVGs), constructed from biologically active cells and biodegradable scaffolds have the potential to overcome these limitations, and provide growth capacity and self-repair. Areas covered: This article outlines the TEVG design, biodegradable scaffolds, TEVG fabrication methods, cell seeding, drug delivery, strategies to reduce wait times, clinical trials, as well as a 5-year view with expert commentary...
April 27, 2017: Expert Review of Medical Devices
https://www.readbyqxmd.com/read/28447486/guidance-to-develop-individual-dose-recommendations-for-patients-on-chronic-hemodialysis
#8
Verena Gotta, Kim Dao, Frédérique Rodieux, Thierry Buclin, Françoise Livio, Marc Pfister
In addition to tailored clinical trials in patients on chronic hemodialysis (HD) during drug development, clinician-initiated post-marketing studies and case reports on individual pharmacokinetic (PK) assessments provide an important source of information about drug dialysability and individualized dose recommendations in this vulnerable population. Areas covered: First, factors that may alter drug exposure in HD patients are explained. Second, available regulatory and methodological guidelines for PK assessments in this population are summarized...
April 27, 2017: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/28447483/the-role-of-adhesions-between-homologous-cancer-cells-in-tumor-progression-and-targeted-therapy
#9
Jie Xia, Yuhao Cheng, Hang Zhang, Rutian Li, Yiqiao Hu, Baorui Liu
Adhesions between homologous cancer cells play an important role in promoting tumor progression and designing tumor-targeting methods. Known as "homologous adhesions" of cancerous cells, these are usually more specific than adhesions to normal cells and heterogenic cells, and they have been widely discovered both in vivo and in vitro. The aberrant expression of cell adhesion-related molecules (CARMs) on each species of cancer cells is mainly responsible for inducing more specific homologous adhesions. Based on the improvement of biomimetic technologies, such adhesion has been investigated and applied deeply in drug delivery systems recently...
April 27, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28447476/mtbvac-from-discovery-to-clinical-trials-in-tuberculosis-endemic-countries
#10
Dessislava Marinova, Jesus Gonzalo-Asensio, Nacho Aguilo, Carlos Martin
BCG remains the only vaccine against tuberculosis (TB) in use today and despite its impressive global coverage, the nature of BCG protection against the pulmonary forms of TB remains subject to ongoing debate. Because of the limitations of BCG, novel TB vaccine candidates have been developed and several have reached the clinical pipeline. One of these candidates is MTBVAC, the first and only TB vaccine in the clinical pipeline to date based on live-attenuated Mycobacterium tuberculosis that has successfully entered clinical evaluation, a historic milestone in human vaccinology...
April 27, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28447475/olaratumab-for-advanced-soft-tissue-sarcoma
#11
Alexander Tobias, Michael P O'Brien, Mark Agulnik
Olaratumab is a humanized IgG1 monoclonal antibody that blocks the platelet-derived growth factor receptor alpha (PDGFRα). Its antagonistic behavior inhibits the receptor's tyrosine kinase activity, thereby, turning off the downstream signaling cascades responsible for soft tissue sarcoma tumorigenesis. In October 2016, olaratumab received Food and Drug Administration (FDA) approval for its use in combination with doxorubicin for treatment of advanced soft tissue sarcoma. Areas covered: This drug profile takes a comprehensive look at the clinical studies leading to FDA approval of olaratumab as well as its safety and efficacy as a front-line treatment option for sarcoma patients...
April 27, 2017: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/28447431/commentary-on-daubresse-et-al-2017-an-epidemic-of-outdated-data
#12
Walid F Gellad
No abstract text is available yet for this article.
June 2017: Addiction
https://www.readbyqxmd.com/read/28447430/commentary-on-rehm-et-al-2017-composition-of-alcoholic-beverages-an-under-researched-dimension-in-the-global-comparative-risk-assessment
#13
Dirk W Lachenmeier, Stephan G Walch
No abstract text is available yet for this article.
June 2017: Addiction
https://www.readbyqxmd.com/read/28446799/expanding-the-spectrum-of-skeletal-dysplasia-with-immunodeficiency-a-commentary-on-identification-of-biallelic-extl3-mutations-in-a-novel-type-of-spondylo-epi-metaphyseal-dysplasia
#14
https://www.readbyqxmd.com/read/28446056/high-technology-augmentative-communication-for-adults-with-post-stroke-aphasia-a-systematic-review
#15
Maria Julieta Russo, Valeria Prodan, Natalia Meda, Lucila Carcavallo, Anibal Muracioli, Liliana Sabe, Lucas Bonamico, Ricardo Allegri, Lisandro Olmos
Augmentative and alternative communication (AAC) systems were introduced into clinical practice by therapists to help compensate for persistent language deficits in people with aphasia. Although, there is currently a push towards an increased focus on compensatory approaches in an attempt to maximize communication function for social interaction, available studies including AAC systems, especially technologically advanced communication tools and systems, known as "high-technology AAC", show key issues and obstacles for these tools to become utilized in mainstream clinical practice...
April 26, 2017: Expert Review of Medical Devices
https://www.readbyqxmd.com/read/28444890/utilizing-pbpk-modeling-to-evaluate-the-potential-of-a-significant-drug-drug-interaction-between-clopidogrel-and-dasabuvir-a-scientific-perspective
#16
V Arya, P Zhao, K S Reynolds, P Mishra, I R Younis
Dasabuvir, a component of VIEKIRA PAK, is a substrate of CYP2C8 enzymes. Prescribing information for VIEKIRA PAK contraindicates gemfibrozil, a strong CYP2C8 inhibitor, because coadministration significantly increases dasabuvir exposures, which may increase the risk of QT prolongation. Clopidogrel may increase dasabuvir exposures primarily due to CYP2C8 inhibition by clopidogrel-acyl-β-D-glucuronide. This commentary outlines the US Food and Drug Administration (FDA) interdisciplinary review team's scientific perspective to address the potential for a significant drug-drug interaction (DDI) between clopidogrel and VIEKIRA PAK...
April 26, 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28444428/commentary-reduction-malarplasty-that-uses-malar-setback-without-resection-of-malar-body-strip
#17
Michael J Yaremchuk, Jeffrey H Lee
No abstract text is available yet for this article.
April 25, 2017: Aesthetic Plastic Surgery
https://www.readbyqxmd.com/read/28443391/atazanavir-sulfate-cobicistat-for-the-treatment-of-hiv-infection
#18
Francisco Antunes
The life expectancy of patients living with HIV has increased significantly in the last two decades, as a result of the great progress in treatment of HIV infection. During this time, several drugs were developed to offer long-term benefits in terms of virologic efficacy, favourable tolerability and toxicity profiles. Pharmacokinetic boosting of protease inhibitors allows a higher genetic barrier, as few or no drug-resistant mutations are detected in patients with virologic failure. Areas covered: Atazanavir sulfate + cobicistat (ATV/c) was recently approved in the United States of America and in the European Union for the treatment of HIV-1 infection...
April 26, 2017: Expert Review of Anti-infective Therapy
https://www.readbyqxmd.com/read/28443360/overview-of-procalcitonin-assays-and-procalcitonin-guided-protocols-for-the-management-of-patients-with-infections-and-sepsis
#19
Philipp Schuetz, Celine Bretscher, Luca Bernasconi, Beat Mueller
Procalcitonin is a surrogate infection blood marker whose levels help estimate the likelihood of bacterial infections and correlate with their resolution. Recent trials have revealed the benefits of inclusion of procalcitonin in antibiotic stewardship protocols for initiation and discontinuation of antimicrobial therapy. Areas covered: Procalcitonin-guided antibiotic stewardship protocols have shown appreciable reductions in antibiotic use and duration of therapy in respiratory infections, sepsis, and other infections, with positive effects on clinical outcomes...
April 26, 2017: Expert Review of Molecular Diagnostics
https://www.readbyqxmd.com/read/28443352/gff-mdi-for-the-improvement-of-lung-function-in-copd-a-look-at-the-pinnacle-1-and-pinnacle-2-data-and-beyond
#20
Klaus F Rabe
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally and incidence rates are continuing to rise. Long-acting bronchodilators are the foundation on which current pharmacological approaches to COPD management are built, with long-acting muscarinic antagonists (LAMAs) and long-acting β2-agonists (LABAs) recommended across the spectrum of the disease continuum. Combining LAMAs and LABAs provides additional lung function improvements and relief of patient symptoms compared with either therapy alone...
April 26, 2017: Expert Review of Clinical Pharmacology
keyword
keyword
26621
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"